Loading…
Anabolic Laboratories Inc was cited for marketing CoQ10 Ubiquinol Prime and Policosanol Microtabs as unapproved new drugs rather than dietary supplements by making disease claims on their website. The company's website contained multiple claims establishing drug intent, including statements that CoQ10 treatment reduced the need for inotropic drugs after surgery, improved symptoms in heart failure patients, and reduced adverse cardiovascular events. These disease-treatment and prevention claims violated the Federal Food, Drug, and Cosmetic Act by positioning the products as drugs without required FDA approval or proper drug labeling.